Journal of Clinical Oncology
Articles in this Issue
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.
4610 Background: Sasanlimab with BCG (induction [IND] + maintenance [MNT]) significantly improved investigator-assessed EFS vs BCG (IND + MNT) and had a m...
Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
TPS8651 Background: OSE2101 (TEDOPI) is a therapeutic cancer vaccine composed of multiple peptides restricted to HLA-A2 ph...
A phase II randomized trial of nano-crystalline megestrol acetate for nutritional improvement in postoperative head and neck squamous cell carcinoma undergoing radiotherapy.
TPS6120 Background: Head and neck squamous cell carcinoma (HNSCC) patients frequently experience malnutrition and weight loss, exacerbated by cancer cache...
Medical oncologist–reported challenges of treating metastatic cancer.
e13576 Background: The treatment of metastatic cancer requires complex resources for effective care delivery. We evaluated associations between challenges...
Organ-agnostic automated RECIST measurements across time points with foundation models.
e13669 Background: RECIST 1.1 remains the gold standard for evaluating tumor response in clinical trials and patient care. However, its reliance on manual...
Incidence and characteristics of mismatch repair (MMR) protein deficient colorectal cancer (CRC) in a community hospital based cancer center in rural central Nebraska.
e22591 Background: MMR protein deficient (dMMR) CRC has distinctive clinical and pathologic features that can be either sporadic or genetic. Immunohistoch...
A phase II study of AK117 combined with cetuximab or AK104 in the treatment of recurrent or metastatic head and neck squamous cell carcinoma after the failure of PD-1 (L1) inhibitors and/or platinum-based therapy.
TPS6114 Background: The administration of first-line pembrolizumab monotherapy or pembrolizumab combined chemotherapy has been shown to improve survival a...
A LAIR-1 targeting antibody drug conjugate for hematologic cancers.
e15022 Background: LAIR-1 is a receptor expressed on the surface of hematopoietic cells subsets that negatively regulates immune activity. It is also high...
Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable <i>EGFR</i> -mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data.
8048 Background: The LAURA trial established concurrent chemoradiotherapy (cCRT) followed by consolidation targeted therapy as the standard for unresectab...
The impact of DNA repair genetic alterations identified by circulating tumor DNA on sensitivity to radium-223 in bone metastatic, castration-resistant prostate cancer.
TPS5120 Background: Selection, timing, and sequencing of therapy for men with bone metastatic castration-resistant prostate cancer (mCRPC) for optimal cli...
A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma.
TPS2096 Background: Glioblastoma (GBM) is associated with dismal prognosis and poor quality of life. In approximately 60% of tumors, the O6-methylguanine...
Cytoreductive nephrectomy for patients with metastatic non-clear cell renal cell carcinoma: Results from a matched 15-year retrospective cohort.
e16537 Background: Upfront cytoreductive nephrectomy (CN) was not associated with improved outcomes in patients (pts) with intermediate or poor-risk clear...
An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).
4076 Background: In the era of immunotherapy, whether neoadjuvant immunochemotherapy (NAIC) would be standard treatment of locally advanced esophageal squ...
Prognostic assessment of breast cancer using clinical and pathological variables of more than 1 million patients.
e13170 Background: Understanding the prognosis of cancer patients based on clinical characteristics is crucial for personalized treatment strategies and c...
Modeling progression and treatment of AML using the Thales QSP software platform.
e18506 Background: Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the abnormal maturation and proliferation of my...
Efficacy and safety of transarterial therapy combined with donafenib plus programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma.
e16210 Background: Hepatocellular carcinoma (HCC) stands as a predominant form of liver cancer, characterized by its aggressive nature and poor prognosis....
Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC; the Janus Rectal Cancer trial).
TPS3650 Background: A total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to neo...
Validation of HistoTME-predicted immune subtypes and immunotherapy outcomes using human interpretable features (HIFs) from H&E images in non-small cell lung cancer.
8583 Background: Tumor microenvironment (TME) plays a critical role in tumor progression and response to treatment, especially in improving the response t...
Real-world use of carboplatin-containing chemotherapy in early triple negative breast cancer (TNBC).
e23285 Background: TNBC is associated with clinically aggressive behavior, limited treatment options, and worse outcomes. Chemotherapy (chemo) guidelines...
Disparities in survival predictors of older cancer patients in Bangladesh: A multicenter study.
e13845 Background: The global aging population has led to increased cancer prevalence among older adults, particularly in low- and middle-income countries...
Clinical utility and patient engagement with a novel digital platform for cancer care navigation.
e13713 Background: Overcoming barriers to care navigation remains a significant challenge in oncology. Patients often describe navigating a treacherous hi...
Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.
e18073 Background: Induction chemotherapy followed by concurrent chemoradiotherapy is the standard treatment for locally advanced nasopharyngeal carcinoma...
Prevalence of homologous recombination deficiency in different molecular subgroups of endometrial carcinomas.
e17631 Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) has been studied to show positive efficacy in endometrial cancer (EC). However, rationa...
Diagnostic performance of artificial intelligence in predicting recurrence after surgical resection of hepatocellular carcinoma (HCC).
e16199 Background: Artificial intelligence (AI) has been suggested as an alternative biomarker for predicting hepatocellular carcinoma (HCC) recurrence af...
Evaluating palliative care needs of early-phase clinical trial patients.
12086 Background: Specialty palliative care (PC) is increasingly recognized as essential for patients (pts) in early phase clinical trials (EPT), as highl...